RecruitingPhase 1NCT05003947
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IBD
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Inflammatory Bowel Disease
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Enrollment
15 participants
Start Date
Jun 11, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of inflammatory bowel disease
Eligibility
Inclusion Criteria2
- Diagnosis of Crohn's disease or Ulcerative Colitis
- Understanding and willingness to sign a written informed consent document
Exclusion Criteria10
- Active infection
- Active cancer
- Chronic multisystem organ failure
- Pregnancy
- Clinically significant Abnormalities on pre-treatment laboratory evaluation
- Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
- Continued drug abuse
- Pre-menopausal women not using contraception
- Previous organ transplant
- Hypersensitivity to sulfur
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALAlloRx
cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05003947
Related Trials
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT0484460666 locations
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883228 locations
Mechanism of Chronic Pain in Patients With IBD
NCT049952241 location
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395206 locations
BOOM-IBD2 Pivotal Clinical Trial
NCT0657166919 locations